Eritrea vs Republic of Moldova: Average cost of multi drug-resistant tuberculosis treatment
Eritrea
793 constant 2022 US$
in 2024
Republic of Moldova
824 constant 2022 US$
in 2024
Eritrea rank
62nd
Republic of Moldova rank
60th
Average cost of multi drug-resistant tuberculosis treatment over time
- Eritrea
- Republic of Moldova
How they compare
Republic of Moldova currently reports 824 constant 2022 US$ against 793 constant 2022 US$ in Eritrea, a difference of 31 constant 2022 US$.
The two have swapped places 3 times across 7 shared years of data; in 2018 it was Eritrea ahead.
Eritrea ranks 62nd and Republic of Moldova ranks 60th of 92 countries.
Eritrea has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Eritrea | Republic of Moldova | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,666 constant 2022 US$ | 2,510 constant 2022 US$ | 156 constant 2022 US$ | Eritrea |
| 2020s | 3,106 constant 2022 US$ | 1,372 constant 2022 US$ | 1,734 constant 2022 US$ | Eritrea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Eritrea or Republic of Moldova?
- Republic of Moldova, at 824 constant 2022 US$ against 793 constant 2022 US$ in Eritrea as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Eritrea and Republic of Moldova?
- 31 constant 2022 US$, with Republic of Moldova ahead.
- How many years of comparable data are there for Eritrea and Republic of Moldova?
- 7 years are reported by both, from 2018 to 2024.
- How do Eritrea and Republic of Moldova rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Eritrea ranks 62nd and Republic of Moldova ranks 60th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.